局灶消融后前列腺影像(PI-FAB)评分系统在局灶冷冻消融和局灶高强度聚焦超声后的阅片者间信度外部验证
本研究回顾性纳入2007至2023年接受局灶治疗的91例患者共113次多参数MRI检查(冷冻消融后95次、HIFU后18次),由三名专科培训放射科医生采用PI-FAB评分系统阅片。结果显示阅片者间一致性较高(Fleiss Kappa 0.71,p<0.001;Gwet AC2 0.70,p<0.03),PI-FAB 3分对诊断临床显著前列腺癌具有高特异度(三名阅片者分别为88%、86%、93%),PI-FAB 1分排除临床显著前列腺癌的敏感度高(分别为88%、78%、84%)。作者认为PI-FAB可有效评估局灶治疗后的多参数MRI复发,但需更大规模多机构研究确认其临床效用。
要点
- PI-FAB评分在局灶冷冻消融和HIFU后多参数MRI中阅片者间一致性较高(Fleiss Kappa 0.71,Gwet AC2 0.70)。
- PI-FAB 3分对诊断临床显著前列腺癌特异度高(三名阅片者分别为88%、86%、93%)。
- PI-FAB 1分排除临床显著前列腺癌敏感度高(三名阅片者分别为88%、78%、84%)。
核心结论
- 本研究提示PI-FAB评分系统可有效评估局灶治疗后的多参数MRI复发,阅片者间信度较高,对冷冻消融和HIFU后预测野内临床显著前列腺癌复发具有高特异度,但需更大规模多机构研究确认其临床效用。
研究设计与样本
- 回顾性、单机构研究,纳入2007至2023年接受局灶治疗且有随访多参数MRI和后续前列腺活检的所有患者,共91例患者113次多参数MRI检查(冷冻消融后95次、HIFU后18次),由三名专科培训放射科医生采用PI-FAB系统评分。
诊断标准与关键数值
- PI-FAB评分3分诊断临床显著前列腺癌的特异度分别为88%、86%、93%(三名阅片者);PI-FAB评分1分排除临床显著前列腺癌的敏感度分别为88%、78%、84%(三名阅片者),基于中位随访14-16个月的监测影像。
临床应用与阅片要点
- 作者认为基于其性能指标,PI-FAB有助于在该患者人群中识别野内复发;作者指出需要更大规模多机构研究确认PI-FAB在临床实践中的效用。
局限性
- 本研究为回顾性、单机构研究。
- 作者指出需要更大规模多机构研究确认PI-FAB在临床实践中的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The efficacy of focal therapy (FT) has improved with the use of multiparametric MRI (mpMRI) for lesion identification, though standardized mpMRI reporting post-FT is lacking. The Prostate Imaging after Focal Ablation (PI-FAB) scoring system was recently introduced to standardize mpMRI interpretation for local recurrence post-FT. This study evaluates the diagnostic performance and inter-reader reliability of PI-FAB following cryoablation and high-intensity focused ultrasound (HIFU) modalities.
MATERIALS AND METHODS: This retrospective, single-institution study included all patients treated with FT from 2007 to 2023 with available follow-up mpMRI and subsequent prostate biopsy. Three fellowship-trained radiologists scored these images using the PI-FAB system. The primary objective was inter-reader agreeability of PI-FAB scores, and the secondary objective assessed performance metrics, including sensitivity, specificity, positive predictive and negative predictive value.
RESULTS: 91 patients with 113 mpMRI exams (95 post-cryotherapy; 18 post-HIFU) were reviewed. There was substantial agreement between the readers (Fleiss' Kappa (κ): 0.71, p < 0.001; Gwet AC2: 0.70, p < 0.03). A PI-FAB score 3 had a significant ability to rule-in csPCa with high specificity (88%, 86%, and 93% per reader, respectively), and PI-FAB score 1 had high sensitivity to rule out csPCa (88%, 78%, and 84% per reader, respectively) in surveillance imaging (14-16 months median follow-up).
CONCLUSIONS: Our study suggests that the PI-FAB scoring system can be effectively used to evaluate mpMRI recurrence post-FT, with substantial inter-reader reliability and high specificity for predicting in-field clinically significant prostate cancer recurrence post-cryotherapy and HIFU. Larger, multi-institutional studies are essential to confirm PI-FAB's utility in clinical practice.
KEY POINTS: Question There is no widely accepted and validated standardized scoring system to predict the local recurrence of clinically significant prostate cancer after focal therapy with ablative modalities. Findings The Prostate Imaging after Focal Ablation (PI-FAB) scoring system effectively predicts in-field recurrence of prostate cancer after focal therapy with substantial inter-reader reliability and specificity. Clinical relevance As patient requests for focal therapy to treat localized low- to- intermediate risk prostate cancer become more common, based on its performance metrics, PI-FAB will aid in identifying in-field recurrence within this patient population.
引用
- Ivey MC, Deivasigamani S, Kotamarti S, et al. External validation of inter-reader reliability of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system following focal cryoablation and focal high-intensity focused ultrasound. Eur Radiol. 2025. PMID: 40172640. doi:10.1007/s00330-025-11513-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。